肝胆胰外科杂志 ›› 2018, Vol. 30 ›› Issue (3): 211-216.doi: 10.11952/j.issn.1007-1954.2018.03.008

• 论著 临床研究 • 上一篇    下一篇

卡培他滨联合替吉奥化疗在胰腺癌术后的临床疗效

易波，唐才喜，李钰琦，谢智钦，陈迅   

  1. 中南大学湘雅医学院附属株洲医院 肝胆胰外科，湖南 株洲 412007
  • 出版日期:2018-05-25 发布日期:2018-05-16
  • 通讯作者: 陈迅，硕士，副主任医师，E-m ail：1010934460@ qq.com 。
  • 作者简介:易波（1984-），男，湖南株洲人，主治医师，硕士。
  • 基金资助:
    湖南省科技计划项目（2016SK 4006）。

Clinical efficacy of Capecitabine combined with S-1 chemotherapy in patients with pancreatic cancer after surgical treatment

YI Bo, TANG Cai-xi, LI Yu-qi, XIE Zhi-qin, CHEN Xun   

  1. Department of Hepatobiliary and Pancreatic Surgery, Affiliated Zhuzhou Hospital of Xiangya Medical College, Central South University, Zhuzhou, Hunan 412007, China
  • Online:2018-05-25 Published:2018-05-16

PDF (PC)

686

摘要：

[摘 要] 目的 探究胰腺癌患者行手术治疗后卡培他滨联合替吉奥对比卡培他滨单药化疗的临床疗效以及对患者免疫功能的影响。方法 对株洲医院于2008年1月至2010年12月收治的48例行手术治疗后的胰腺癌患者进行前瞻性分析，随机分为对照组和观察组，每组24例，对照组采用卡培他滨单药化疗，观察组采用卡培他滨联合替吉奥化疗。采用生活质量核心量表（QLQ-C30）评估患者生活质量，流式细胞仪检测淋巴细胞亚群，ELISA法检测IFN-γ和IL-4水平，再从脱发、骨髓抑制、肾功能损伤、消化道不良反应和神经毒性五个方面分析两组患者的毒副反应，回访分析两组患者的远期生存率。结果 观察组化疗后缓解率和总有效率分别为41.67%和70.83%，明显高于对照组的25.00%和58.33%；观察组化疗后2周、4周和8周时生活质量均明显优于对照组；以上差异均具有统计学意义（P<0.01）。观察组联合化疗后的T细胞（CD3 + ）、Th细胞（CD3 + CD4 + ）、Tc细胞（CD3 + CD8 + ）、NK细胞（CD3 - CD56 + ）和Treg细胞（CD4 + CD25 + ）百分率增加，IFN-γ水平上升，IL-4水平降低，与化疗前相比，差异均具有统计学意义（P<0.01）。另外，观察组脱发、肾功能损伤、骨髓抑制、消化道不良反应和神经毒性等没有明显增加（P>0.05）。观察组中位生存时间明显长于对照组（25个月 vs 10个月）；观察组的1、2、3年生存率分别为62.5%、54.2%和45.8%，也明显高于对照组（分别为33.3%、25.0%、16.7%），差异具有统计学意义（P<0.05）。结论 卡培他滨联合替吉奥对胰腺癌术后患者具有较高的化疗效果，可显著改善患者的生活质量，提高远期生存率，且不增加不良反应发生率；同时该方式提高机体免疫功能，可成为手术后胰腺癌患者辅助治疗的有效选择。

关键词: 胰腺癌, 卡培他滨, 替吉奥, 免疫功能, 生存分析

Abstract:

Abstract objective To investigate the clinical efficacy of Capecitabine combined with S-1 chemotherapy and its effect on immune function in patients with pancreatic cancer after surgical treatment. Methods A total of 48 patients with pancreatic cancer who enrolled in our hospital from Jan. 2008 to Dec. 2010, were randomly divided into control group and observation group. Twenty-four patients in control group were treated with Capecitabine alone, and additional 24 patients in observation group were treated with Capecitabine plus S-1 chemotherapy. Lymphocyte subsets was detected by flow cytometry, and the levels of IFN-γ and IL-4 were detected by ELISA. Furthermore, the life quality, side effects and long-term survival rate were also analyzed. Results The remission rate and total effective rate in the observation group were 41.67% and 70.83%, respectively, which were significantly higher than those in the control group (25.00% and 58.33%) (P<0.01). The
life quality in the observation group was significantly better than that in the control group at 2, 4 and 8 weeks after chemotherapy (P<0.01). The proportion of T cells (CD3 + ), Th cells (CD3 + CD4 + ), Tc cells (CD3 + CD8 + ), NK cells (CD3 - CD56 + ) and Treg cells (CD4 + CD25 + ) all increased, and the level of IFN-γ also increased, but the level of IL-4 decreased in the observation group after chemotherapy (P<0.01). In addition, there was no significant increase in the side effects of hair loss, renal injury, myelosuppression, gastrointestinal adverse reactions and neurotoxicity in the observation group (P>0.05). The median survival time in the observation group was significantly longer than that in the control group (25.00 months vs 10.00 months, P<0.05); the 1, 2, and 3 year survival rates in the observation group were 62.5%, 54.2% and 45.8%, respectively, which were significantly higher than those in the control group (33.3%, 25.0%, 16.7%, respectively; P<0.05). Conclusion Capecitabine combined with S-1 has a high therapeutic effect on postoperative patients with pancreatic cancer, which can improve the life quality, long-term survival rate, and the immune function, and which does not increase the incidence of adverse reactions. This
programme may become an effective choice for patients with pancreatic cancer after surgery.

Key words: pancreatic cancer, Capecitabine, S-1, efficacy, immune function, survival analysis

中图分类号: 

  • R735.9
[1] 郑立平, 沈亦钰, 胡春东, 陈徐艰, 费发明, 王兢.
NLRP3信号通路在胰腺癌发生发展中的作用机制研究进展
[J]. 肝胆胰外科杂志, 2024, 36(1): 50-54.
[2] 陈磊, 何超, 刘攀, 付强, 张宏伟, 秦涛.
组蛋白去乙酰基转移酶2在胰腺癌中作用机制及治疗的研究进展
[J]. 肝胆胰外科杂志, 2023, 35(9): 568-572.
[3] 蔡凤军, 王晓栋, 杨永生.
胰腺癌行胰十二指肠切除术中淋巴结清扫的争议与思考
[J]. 肝胆胰外科杂志, 2023, 35(8): 449-453，458.
[4] 朱坤忠, 张跃伟.
胰腺癌肝转移介入治疗的研究进展
    [J]. 肝胆胰外科杂志, 2023, 35(8): 507-512.
[5] 李张辉, 李格辉, 刘烨磊, 傅俊辉, 陆才德, 黄静.
胰腺癌术后子宫复发转移一例
[J]. 肝胆胰外科杂志, 2023, 35(7): 433-435.
[6] 王韬 , 沈亦钰.
PARP抑制剂在胰腺癌治疗中的应用及耐药性研究进展
[J]. 肝胆胰外科杂志, 2023, 35(5): 316-320.
[7] 易波, 杨召铭, 唐才喜, 赵志坚.
可切除或交界可切除胰腺癌新辅助治疗+手术与直接手术治疗的临床对比
[J]. 肝胆胰外科杂志, 2023, 35(2): 96-100.
[8] 郭世伟.
局部晚期胰腺癌的治疗进展
[J]. 肝胆胰外科杂志, 2023, 35(2): 120-128.
[9] 全棋, 管时伟, 林泉, 彭明晖, 俞海波.
搭载吉西他滨的SiO2@Fe3O4纳米材料抑制裸鼠胰腺癌移植瘤生长的实验研究
[J]. 肝胆胰外科杂志, 2023, 35(12): 747-752，756.
[10] 盛秋, 张灿, 陈沛.
基于Triangle理论的延续性护理对胰腺癌患者术后营养不良发生风险及程度的影响
[J]. 肝胆胰外科杂志, 2023, 35(11): 680-684.
[11] 申雪晗, 周江敏, 张志伟, 陈孝平. NLR对TACE联合仑伐替尼及免疫治疗的中晚期肝癌患者预后的预测价值[J]. 肝胆胰外科杂志, 2023, 35(1): 19-24.
[12] 杜岩, 姜文凯, 李昕, 周文策. KPNA4在胰腺癌中高表达并且与不良预后相关[J]. 肝胆胰外科杂志, 2022, 34(8): 488-494.
[13] 刘松柏, 刘鹏, 王兴, 朱昌毫, 费晓斌, 蔡浚哲, 潘耀振. TPM4对人胰腺癌细胞侵袭和迁移的影响[J]. 肝胆胰外科杂志, 2022, 34(8): 495-500.
[14] 王哲近, 李晨, 麻忠武, 宋洪亮, 俞海波. 长链非编码RNA LINC00606对胰腺癌细胞增殖、侵袭及迁移的影响[J]. 肝胆胰外科杂志, 2022, 34(5): 288-294.
[15] 胡春东, 王兢, 郑立平, 陈徐艰, 费发明, 沈亦钰. 血浆D-二聚体与胰腺癌患者临床病理特征及预后的相关性[J]. 肝胆胰外科杂志, 2022, 34(4): 210-213.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright © 2017 肝胆胰外科杂志 All Rights Reserved.
电话/传真：0577-86699363　E-mail: gdywkzz@vip.126.com
地址：浙江省温州市茶山高教园区温州医科大学图书馆A411室　邮编：325035
本系统由北京玛格泰克科技发展有限公司设计开发　技术支持：support@magtech.com.cn